Sylvia S. Ng, Ph.D.
Affiliations: | 2002 | University of Toronto, Toronto, ON, Canada |
Area:
Pharmacology, OncologyGoogle:
"Sylvia Ng"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| David Hedley | grad student | 2002 | University of Toronto | |
| (Preclinical evaluation of inhibitors of the phosphatidylinositide 3-kinase/protein kinase B cell survival pathway in the treatment of pancreatic cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yapp DT, Wong MQ, Kyle AH, et al. (2016) The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis |
| Donohue E, Thomas A, Maurer N, et al. (2013) The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. Journal of Cancer. 4: 585-96 |
| Ng SS, Figg WD. (2004) Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biology & Therapy. 3: 1212-3 |
| Ng SS, Tsao MS, Nicklee T, et al. (2002) Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Molecular Cancer Therapeutics. 1: 777-83 |
| Ng SS, Tsao MS, Nicklee T, et al. (2001) Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 3269-75 |